The Generative Brain
Blueprint Genetics logo

Blueprint Genetics

Blueprint Genetics Oy is a clinical genetic testing laboratory founded in 2012 in the Helsinki area of Finland and owned by Quest Diagnostics since January 2020. Its Espoo laboratory holds CAP, CLIA and ISO 15189 accreditation, and since August 2024 all testing, including for US clients, is done there. For prion disease it offers PRNP within its NGS Dementia Panel (NE2301); an earlier stand alone PRNP single gene test page now returns not found. Ordering is by healthcare professionals only, with no published prices, and octapeptide repeat insertion detection is not stated. Information only.

Key facts

  • Founded in 2012; legal entity Blueprint Genetics Oy, headquartered in the Helsinki area with its laboratory at Keilaranta 16, Espoo; mission stated as giving clinicians and patients high quality tools to diagnose genetic conditions.
  • Quest Diagnostics completed the all cash acquisition on 21 January 2020 for USD 108 million net of USD 3 million cash acquired; it was announced on 22 January 2020.
  • At acquisition the company had a Helsinki laboratory and a Seattle hub, more than 3,900 single gene tests and over 200 panels in 14 specialties, with CEO Tommi Lehtonen staying on.
  • Since 4 December 2025 the business is led by Juhana Rauramo as Vice President and General Manager, reporting to Quest SVP Oncology and Genomics Mark Gardner, with remit over EMEA and rest of world markets.
  • The Espoo laboratory lists CAP 9257331 (to April 2028), ISO 15189 T292 from FINAS (to February 2028) and CLIA 99D2092375 (to April 2027), plus four US state licences.
  • From 15 August 2024 specimen testing in the US stopped and US samples are processed in Helsinki under an updated services agreement with institutional US dollar billing; New York orders are not accepted outside sponsored programs.
  • PRNP is included in the Dementia Panel NE2301, which lists Creutzfeldt-Jakob disease, Gerstmann-Straussler disease and fatal familial insomnia among PRNP phenotypes, with a 4 week turnaround.
  • The panel uses NGS sequence analysis plus deletion and duplication analysis on EDTA blood, extracted DNA or saliva; it states repeat expansion disorders are not detected unless specifically mentioned and says nothing about PRNP octapeptide repeat insertions.
  • A search excerpt describes a PRNP single gene test, code S01488, with a 3 to 4 week turnaround, but the page returned 404 on 2026-10-16 and a GTR search for PRNP plus Blueprint returned only the Dementia Panel record.
  • Only qualified healthcare professionals can order, through the Nucleus portal or paper requisition; the general terms exclude direct to patient services.
  • No prices are published on the panel or ordering pages; pricing is by regional sales contact.
  • In the NCBI GTR, Blueprint is one of several labs listing PRNP, alongside Labcorp Genetics, Fulgent Genetics, CeGaT and DNA Labs India.
  • The contact page names no office, partner or distributor in India or elsewhere in Asia; listed regions are the Americas, Europe, Australia and the Middle East.

Timeline

  1. 2012Blueprint Genetics founded in the Helsinki capital region.
  2. 2020Quest Diagnostics completes the acquisition of Blueprint Genetics Oy.
  3. 2020Acquisition announced publicly.
  4. 2024My Retina Tracker program ends.
  5. 2024US specimen testing discontinued; all testing moves to the Helsinki laboratory.
  6. 2024US lab operations page last modified.
  7. 2025Dementia Panel page, which includes PRNP, last updated.
  8. 2025Juhana Rauramo announced as Vice President and General Manager.
  9. 2026Stand alone PRNP single gene test page returns not found.
Sources for this page